

NEWSLETTER



ALERT HANDLING AND MAH INVOICING PROCESS

Firstly, OSMR would like to express its gratitude to the pharmaceutical companies, which, having understood the importance of this dynamic European serialization project, are proactively communicating their findings related to alerts raised by the National Medicines Verification System (NMVS).

The Operational Department can then use this information to label the false alerts which are related to issues such as: data not uploaded into the EU Hub or scanner configuration.

Such a collaborative environment is a prerequisite in fostering an operational European Medicines Verification System (EMVS).

The result of this fruitful collaboration and common effort is the alert percentage which, within the last few weeks has been **getting closer to the established European target of 0,05% alerts generated, a strong indicator of a mature system.**

Secondly, another important aspect which needs to be acknowledged is the timely manner in which the payment of the annual invoice has been and is processed. As we have outlined in previous communications, the financial burden of implementing the serialization project has fallen upon the shoulders of the **pharmaceutical companies** which, especially in these troubled times, **are placing great emphasis on enabling patients' access to authenticated medicines.**

The invoicing flow is the following: the invoicing process starts in September of every year, enabling sufficient time to the companies which require a Purchase Order (PO) number on the invoice, to acquire one.

The deadline for the invoice payment is 30 days, if after this interval the payment has not been processed, a kind reminder is sent for finalizing the payment in 30 days. Furthermore, after that time-frame, another reminder is sent with a deadline for another 15 days.




The final deadline for finalizing the payment is usually set around December 15th, which is also announced every year in our Newsletters.

This process has been established in such a way that it enables OSMR to ensure that the payments to the blue-print supplier of the National Medicines Verification System – Arvato and to the European Medicines Verification Organisation (EMVO) are covered and thus contribute to the functionality and operational aspect of the EMVS.

NATIONAL MEDICINES VERIFICATION SYSTEM (NMVS) AND REPORTING TOOL IMPLEMENTATION OVERVIEW – 2019 & 2020

As a great deal of work and effort is being put into the fine-tuning and constant improvement of this dynamic system, we wanted to offer a glimpse into the overview of the updates which have been implemented to the NMVS and the Reporting Tool throughout the period: 2019 – 2020.

You can find this information also on our site: [System Status](#)



TESTING IN THE NMVS TEST ENVIRONMENT (IQE)

OSMR reiterates the request addressed to the **End-Users to finalize the mandatory tests in the NMVS test environment (IQE)**.

After the tests have been completed and the subsequent report has been uploaded to the SIMI (Registering and Incident Management System) application, kindly inform us via email at the following address: suport.cont.snmv@osmr.ro

An example of filling-in the above-mentioned report can be found on our site: [IQE Testing](#)

NMVS CERTIFICATES

Whenever an End-User connects to the NMVS, it uses a certificate which has been previously generated so as to convey the legitimacy of the respective End-User.

The above-mentioned certificate has a validity of 2 years and an automated email is sent by the system 60 days prior to the expiration date. When it expires, the End-User can no longer connect to the system.

Thus, a new certificate needs to be downloaded and installed in the NMVS. You can find the necessary steps for this process described in more detail on [our website](#).

As there are organizations with a large number of End-Users, **a new functionality is now available in both IQE and PRD environment of the NMVS which enables the system Administrators to renew these certificates in bulk**, saving thus valuable time throughout this process.

EU HUB RELEASE 1.8

At the end of October, EMVO has officially announced that **Release 1.8 has been successfully deployed to IQE** (test environment).

As for the deployment dates of Release 1.8 to the PRD (Production) environment, EMVO will provide updates in due course.

